Humana To Divest End-Of-Life Care Business For $900 Million
Humana said it signed a definitive agreement to sell its minority stake in Gentiva, an end-of-life services provider, for $900 million to a consortium of investors. Humana plans to use proceeds for general corporate purposes; the deal is expected to close in Q3 pending regulatory approvals. The sale follows Humana’s earlier Kindred at Home divestiture plans.
The $900M divestiture is a balance-sheet/capital-allocation catalyst for Humana and may reduce exposure to end-of-life care operations.
Humana signed a definitive agreement to divest its minority interest in Gentiva for $900 million, with Q3 close pending regulatory approvals.
Near-term volatility possible around deal-signing/regulatory headlines; direction likely depends on how investors view proceeds use and any earnings impact from reduced Gentiva exposure.
Background
Humana has been exiting “non-core” Kindred at Home hospice/palliative businesses, which were restructured and rebranded into Gentiva.
Why it matters
The definitive agreement formalizes the monetization of Humana’s Gentiva minority interest and sets up a Q3 regulatory approval timeline; proceeds are earmarked for general corporate purposes.
Market relevance
A large, time-bound divestiture creates a discrete catalyst for HUM around deal progression and any regulatory developments.
Market effects
Signals continued portfolio reshaping among Medicare Advantage/health services players toward “core” insurance and CenterWell-style services.
Limited direct regional impact; primarily US healthcare services/MA capital allocation.
Low; transaction is US-focused with domestic regulatory approvals.
Alternative perspectives
Because Humana is selling only a minority stake, the earnings impact may be smaller than the headline $900M suggests, limiting upside to the stock.
Traders may need to watch regulatory approval risk and the stated use of proceeds (general corporate purposes) for any implied leverage reduction vs. reinvestment.
Key entities
- companyHumana
Medicare Advantage insurer announcing the Gentiva minority-stake divestiture for $900 million.
- companyGentiva
End-of-life services provider (hospice and palliative care) in which Humana holds a minority interest.
